New drug combo shows promise in slowing rare gut tumors
NCT ID NCT01744249
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding the drug axitinib to standard sandostatin LAR therapy could slow tumor growth in 256 people with advanced neuroendocrine tumors (G1-G2) that started outside the pancreas. Participants received either the combination or sandostatin plus a placebo. The main goal was to see how long it took for the cancer to worsen. Results could lead to a new treatment option for this rare cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axitinib (a drug that blocks blood vessel growth to tumors) and sandostatin LAR (a hormone-like drug that slows tumor growth)
What this could lead to
If it works, this combination could slow tumor growth and delay disease progression in people with advanced neuroendocrine tumors.
What could go wrong
This is a mid-stage trial, so results are not yet proven. Axitinib can cause side effects like high blood pressure, fatigue, and diarrhea. The benefit may be small or not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria di Perugia
Perugia, 06129, Italy
-
Clatterbridge Cancer Centre
Bebington, Wirral, CH63 4JY, United Kingdom
-
Complejo Hospitalario Univ A Coruña
A Coruña, Spain
-
Hospital Alvaro Cunqueiro
Vigo, Pontevedra, 36312, Spain
-
Hospital Central de Asturias
Oviedo, Principality of Asturias, Spain
-
Hospital Clara Campal
Madrid, Spain
-
Hospital Clínico San Carlos
Madrid, Spain
-
Hospital General Universitario de Valencia
Valencia, 46014, Spain
-
Hospital Gregorio Marañón
Madrid, Spain
-
Hospital Marqués de Valdecilla
Santander, Spain
-
Hospital Univ La Paz
Madrid, Spain
-
Hospital Univ de Salamanca
Salamanca, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, Malaga, 29010, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Hospital Universitario de Burgos
Burgos, Spain
-
Hospital Virgen de las Nieves
Granada, Spain
-
Hospital de Donostia
Donostia / San Sebastian, Spain
-
Hospital universitario de Leon
León, Spain
-
Institut Català d'Oncologia L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Marburg Universitätsklinikum Giessen und Marburg GmbH
Marburg, 35043, Germany
-
Sapienza, Universitá di Roma, Ospedale sant'Andrea
Rome, 00189, Italy